Financial Disclosure Appendix for PHS-Funded Research (Form 510)

Please type your responses in the form.

I. Investigator Information				
Disclosing Individual: Department:		Academic Title:		
•	<u>'</u>			
Email:	Allitual Reporting/Renewal/	Supplemental Funding		
Principal Investigator:		PHS Award Number:		
Project Title:		The Attack Talliaci		
II. Disclosure	agarding any significant financial interests r	alated to the Disclosing Individual's institutional responsibilities		
Please provide information regarding any significant financial interests related to the Disclosing Individual's institutional responsibilities.				
Entity Name	Disclosure Type (Check all that apply)	Do these interests relate to the above referenced PHS funded research project? Please provide an explanation for your response.		
	☐ Income: \$	☐ Yes ☐ No		
☐ Publicly Traded	☐ Stock and/or Stock Options	Explanation:		
☐ Non-Publicly Traded	Number of Shares:			
For new Significant Financial	Estimated Current Stock Value: \$ % of Issued & Outstanding Shares:			
Interests, did you acquire				
the interest in the past 30	☐ IP (royalties, license fees, etc.)			
days? □ Yes □ No	(,,,,			
	☐ Income: \$	☐ Yes ☐ No		
□ Publicly Traded		Explanation:		
☐ Non-Publicly Traded	☐ Stock and/or Stock Options	2.50		
·	Number of Shares: Estimated Current Stock Value: \$			
For new Significant Financial	% of Issued & Outstanding Shares:			
Interests, did you acquire the interest in the past	□ <5% □6-10% □11-25% □>26	%		
30 days? ☐ Yes ☐ No	☐ IP (royalties, license fees, etc.)			
	☐ Income: \$	□ Yes □ No		
☐ Publicly Traded	☐ Stock and/or Stock Options	Explanation:		
☐ Non-Publicly Traded	Number of Shares:			
For new Significant Financial	Estimated Current Stock Value: \$ % of Issued & Outstanding Shares:			
Interests, did you acquire	% of issued & Outstanding Shares. □ <5% □ 6-10% □ 11-25% □ >26	%		
the interest in the past	☐ IP (royalties, license fees, etc.)			
30 days? ☐ Yes ☐ No	☐ Income: \$			
—— □ Publicly Traded	, 	☐ Yes ☐ No Explanation:		
□ Non-Publicly Traded	☐ Stock and/or Stock Options			
	Number of Shares: Estimated Current Stock Value: \$			
For new Significant Financial	% of Issued & Outstanding Shares:			
Interests, did you acquire the interest in the past	□ <5% □6-10% □11-25% □>26	%		
30 days? ☐ Yes ☐ No	☐ IP (royalties, license fees, etc.)			
	☐ Income: \$	☐ Yes ☐ No		
☐ Publicly Traded	☐ Stock and/or Stock Options	Explanation:		
☐ Non-Publicly Traded	Number of Shares:			
For new Significant Financial	Estimated Current Stock Value: \$			
Interests, did you acquire	% of Issued & Outstanding Shares: □ <5% □ 6-10% □ 11-25% □ >26	%		
the interest in the past	☐ IP (royalties, license fees, etc.)			
30 days? □ Yes □ No				

Attach additional sheets as necessary.

University of California, Riverside Form 510 (revised 5.22.17)

Financial Disclosure Appendix for PHS-Funded Research (Form 510)

Please type your responses in the form.

III.	Daimhurcad	or Sponsored	Traval
111.	Reillibursea	or sponsored	Have

<u>Exclude</u> travel that is reimbursed or sponsored by a U.S. federal, state, or local government agency, an Institution of higher education as defined by <u>20 U.S.C. 1001(a)</u>, an academic teaching hospital, a medical center, or a research institute affiliated with Institution of higher education. *Attach additional sheets as necessary.*

Past Travel (last 12 months in excess of \$5,000 per entity)

Entity	Destination	Duration	Purpose of Trip

Planned Travel (upcoming 12 months)

Any reimbursed or sponsored travel in excess of \$5,000 per entity *not* included below will need to be reported to the PRO Office within 30 days after the travel occurs.

- If reporting newly acquired travel interests only, please complete the PHS Travel Update (Form 515).
- For all other disclosures of newly acquired/discover significant financial interests please complete the Financial Disclosure Appendix for PHS-Funded Research (Form 510).

Entity	Destination	Duration	Purpose of Trip
	☐ Continental US	☐ 1-5 Days ☐ 6-10	
	☐ Other	Days Over 10 Days	
	☐ Continental US	☐ 1-5 Days ☐ 6-10	
	☐ Other	Days Over 10 Days	
	☐ Continental US	☐ 1-5 Days ☐ 6-10	
	☐ Other	Days Over 10 Days	
	☐ Continental US	☐ 1-5 Days ☐ 6-10	
	☐ Other	Days ☐ Over 10 Days	

IV. Acknowledgment and Certification

I certify under penalty of perjury that this is a complete disclosure of all my financial interests related to my institutional responsibilities and I have used all reasonable diligence in preparing this Financial Interest Disclosure, and to the best of my knowledge it is true and complete. I also acknowledge that by signing my name below that it is my responsibility to disclose, within 30 days, any new significant financial interests obtained during the term of the above proposed project. Please note electronic or scanned signatures are acceptable; inserting a jpeg of the signature is also acceptable.

Signature: _	Date:	
Jigi latar C.	 Date	

The information provided herein may be released or transmitted to the sponsor, including federal agency representatives, and according to the California Public Records Act, may also be released to the public, upon request. These records will be retained for 3 years after termination of sponsored project or until resolution of any action by the sponsor, whichever is greater. The Office of Record is the Research and Development Office.

V. Definitions

- Income includes salary, consulting fees, honoraria, paid authorship, income received related to intellectual property rights and interests, etc. not paid by or assigned to the UC Regents.
- Institutional Responsibilities is defined as teaching/education, research, outreach, clinical service, training and University and public service, on behalf of UCI and directly related to those credentials, expertise and achievements upon which the Investigator's UCR position is based.
- A Related Significant Financial Interest to the Investigator's institutional responsibilities may include but are not limited to: 1) income or honoraria received for activities such as providing expert testimony or consulting services, serving on a board of directors, scientific advisory board, committee, panel or commission sponsored by a for-profit or non-profit organization, including professional or scholarly societies; acting in an editorial capacity for a professional journal or reviewing journal manuscripts, book manuscripts, or grant or contract proposals for a non-profit or for-profit organization; accepting a position as a salaried employee outside the University or receiving royalty payments for intellectual property rights held by an entity other than The Regents; 2) holding stock or stock options in a company that is developing, manufacturing or selling products or providing services used in an Investigator's clinical practice, teaching, research, administrative or committee responsibilities; or 3) travel paid for or reimbursed by an outside entity.